As the rate-limiting step in Aβ production, BACE1 inhibition has emerged as a key drug target for the therapeutic intervention of the progression of AD in order to prevent the accumulation of toxic Aβ [9,10]. This evidence concerns the gene BACE1 and Alzheimer disease.